The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 797-807

  Artero, Arturo ^a   Tarín, Juan J ^b   Cano, Antonio ^a,b  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

contraceptive; estrogen; hormone therapy; SERM; thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BAZEDOXIFENE; CONTRACEPTIVE AGENT; ESTROGEN; ETHINYLESTRADIOL; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; HEMOSTASIS; HORMONAL THERAPY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ESTROGENS; FEMALE; HEMOSTASIS; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THROMBOSIS;

EID: 84868566314     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328883     Document Type: Article

References (98)

1. Roger V. L., Go A. S., Lloyd-Jones D. M., et al. Executive summary: heart disease and stroke statistics2012 update: a report from the American Heart Association. Circulation: 2012; 125 1 188 197
2. Lobo R. A. Menopause and stroke and the effects of hormonal therapy. Climacteric: 2007; 10 02 27 31 (Pubitemid 47450835)
3. White R. H. The epidemiology of venous thromboembolism. Circulation: 2003; 107 23 01 I4 I8 (Pubitemid 41289265)
4. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost: 2000; 83 5 657 660
5. de Gooyer M. E., Deckers G. H., Schoonen W. G., Verheul H. A., Kloosterboer H. J. Receptor profiling and endocrine interactions of tibolone. Steroids: 2003; 68 1 21 30 (Pubitemid 35422732)
6. Cano A., Hermenegildo C. Modulation of the oestrogen receptor: a process with distinct susceptible steps. Hum Reprod Update: 2000; 6 3 207 211 (Pubitemid 30348889)
7. Blanco-Molina M. A., Lozano M., Cano A., Cristobal I., Pallardo L. P., Lete I. Progestin-only contraception and venous thromboembolism. Thromb Res: 2012; 129 5 e257 e262
8. Tchaikovski S. N., Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res: 2010; 126 1 5 11
9. Odlind V., Milsom I., Persson I., Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand: 2002; 81 6 482 490
10. Raps M., Helmerhorst F., Fleischer K., et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost: 2012; 10 6 992 997 10.1111/j.1538-7836.2012.04720
11. Cano A., Hermenegildo C., Oviedo P., Tarín J. J. The risk for cardiovascular disease in women: from estrogens to selective estrogen receptor modulators. Front Biosci: 2007; 12 49 68 (Pubitemid 46852827)
12. Jayachandran M., Miller V. M. Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets: 2003; 14 2 75 81 (Pubitemid 36461463)
13. Miller V. M., Jayachandran M., Hashimoto K., Heit J. A., Owen W. G. Estrogen, inflammation, and platelet phenotype. Gend Med: 2008; 5 suppl A S91 S102 (Pubitemid 351455234)
14. 2+ mobilization and P-selectin (CD62P) expression in platelets examined under flow cytometry. Blood Coagul Fibrinolysis: 2004; 15 1 1 8 (Pubitemid 38534678)
15. Boudoulas K. D., Montague C. R., Goldschmidt-Clermont P. J., Cooke G. E. Estradiol increases platelet aggregation in Pl(A1/A1) individuals. Am Heart J: 2006; 152 1 136 139 (Pubitemid 43974731)
16. Dobrydneva Y., Weatherman R. V., Trebley J. P., et al. Tamoxifen stimulates calcium entry into human platelets. J Cardiovasc Pharmacol: 2007; 50 4 380 390 (Pubitemid 350303815)
17. Shah V. P., Chegini H. A., Vishneski S. R., Weatherman R. V., Blackmore P. F., Dobrydneva Y. Tamoxifen promotes superoxide production in platelets by activation of PI3-kinase and NADPH oxidase pathways. Thromb Res: 2012; 129 1 36 42
18. Nayak M. K., Singh S. K., Roy A., Prakash V., Kumar A., Dash D. Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen. Thromb Haemost: 2011; 106 4 624 635
19. Chang Y., Lee J. J., Chen W. F., Chou D. S., Huang S. Y., Sheu J. R. A novel role for tamoxifen in the inhibition of human platelets. Transl Res: 2011; 157 2 81 91
20. Cano A., Hermenegildo C., Oviedo P., Tarín J. J. Selective estrogen receptor modulators and risk for coronary heart disease. Climacteric: 2007; 10 2 97 111 (Pubitemid 46482172)
21. Vogelvang T. E., van der Mooren M. J., Mijatovic V. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treat Endocrinol: 2004; 3 2 105 115 (Pubitemid 38337561)
22. Bertina R. M. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb 2003/2004; 33 5-6 395 400 (Pubitemid 40278714)
23. Cano A., Van Baal W. M. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas: 2001; 40 1 17 38 (Pubitemid 33048840)
24. Dahlbäck B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA: 1993; 90 3 1004 1008 (Pubitemid 23053939)
25. Tans G., Bouma B. N., Büller H. R., Rosing J. Changes of hemostatic variables during oral contraceptive use. Semin Vasc Med: 2003; 3 1 61 68 (Pubitemid 37045875)
26. Eilertsen A. L., Liestol S., Mowinckel M. C., Hemker H. C., Sandset P. M. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost: 2007; 97 6 938 943 (Pubitemid 46939206)
27. Fair D. S., Marlar R. A., Levin E. G. Human endothelial cells synthesize protein S. Blood: 1986; 67 4 1168 1171 (Pubitemid 16116436)
28. Lupu C., Zhu H., Popescu N. I., Wren J. D., Lupu F. Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen. Blood: 2011; 118 16 4463 4471
29. Dahm A. E., Iversen N., Birkenes B., Ree A. H., Sandset P. M. Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1. BMC Cardiovasc Disord: 2006; 6 40
30. Rossouw J. E., Anderson G. L., Prentice R. L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA: 2002; 288 3 321 333 (Pubitemid 34761611)
31. Rossouw J. E., Prentice R. L., Manson J. E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA: 2007; 297 13 1465 1477 (Pubitemid 46556472)
32. Mishell D. R. Jr. Oral contraception: past, present, and future perspectives. Int J Fertil: 1992; 37 01 7 18
33. Curtis K. M., Chrisman C. E., Peterson H. B. WHO Programme for Mapping Best Practices in Reproductive Health Contraception for women in selected circumstances. Obstet Gynecol: 2002; 99 6 1100 1112 (Pubitemid 34621238)
34. Petitti D. B. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med: 2003; 349 15 1443 1450 (Pubitemid 37211060)
35. Khader Y. S., Rice J., John L., Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception: 2003; 68 1 11 17 (Pubitemid 37271985)
36. Baillargeon J. P., McClish D. K., Essah P. A., Nestler J. E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab: 2005; 90 7 3863 3870 (Pubitemid 41058144)
37. Margolis K. L., Adami H. O., Luo J., Ye W., Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril: 2007; 88 2 310 316 (Pubitemid 47212162)
38. Petitti D. B., Sidney S., Bernstein A., Wolf S., Quesenberry C., Ziel H. K. Stroke in users of low-dose oral contraceptives. N Engl J Med: 1996; 335 1 8 15 (Pubitemid 26230807)
39. Schwartz S. M., Siscovick D. S., Longstreth W. T. Jr., et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med: 1997; 127 8 pt 1 596 603
40. Siritho S., Thrift A. G., McNeil J. J., et al. Risk of ischemic stroke among users of the oral contraceptive pill: the Melbourne Risk Factor Study (MERFS) Group. Stroke: 2003; 34 7 1575 1580 (Pubitemid 36842604)
41. Anderson G. L., Limacher M., Assaf A. R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA: 2004; 291 14 1701 1712 (Pubitemid 38489892)
42. LaCroix A. Z., Chlebowski R. T., Manson J. E., et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA: 2011; 305 13 1305 1314
43. Bath P. M., Gray L. J. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ: 2005; 330 7487 342
44. Viscoli C. M., Brass L. M., Kernan W. N., Sarrel P. M., Suissa S., Horwitz R. I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med: 2001; 345 17 1243 1249 (Pubitemid 34951488)
45. Simon J. A., Hsia J., Cauley J. A., et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation: 2001; 103 5 638 642 (Pubitemid 32144190)
46. Cummings S. R., Ettinger B., Delmas P. D., et al. The effects of tibolone in older postmenopausal women. N Engl J Med: 2008; 359 7 697 708
47. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med: 2006; 355 2 125 137 (Pubitemid 44050394)
48. Fisher B., Costantino J. P., Wickerham D. L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst: 1998; 90 18 1371 1388 (Pubitemid 28439961)
49. Vogel V. G., Costantino J. P., Wickerham D. L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA: 2006; 295 23 2727 2741
50. Bushnell C. D., Goldstein L. B. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology: 2004; 63 7 1230 1233 (Pubitemid 39350022)
51. Silverman S. L., Christiansen C., Genant H. K., et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res: 2008; 23 12 1923 1934
52. de Villiers T. J., Chines A. A., Palacios S., et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int: 2011; 22 2 567 576
53. Cummings S. R., Ensrud K., Delmas P. D., et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med: 2010; 362 8 686 696
54. Zhou W. B., Ding Q., Chen L., Liu X. A., Wang S. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res Treat: 2011; 128 3 625 631
55. Jordan W. M. Pulmonary embolism. Lancet: 1961; 2 1146 1147
56. Thorogood M., Mann J., Murphy M., Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol: 1992; 21 1 48 52
57. Vandenbroucke J. P., Koster T., Briët E., Reitsma P. H., Bertina R. M., Rosendaal F. R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet: 1994; 344 8935 1453 1457 (Pubitemid 24351698)
58. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet: 1995; 346 8990 1575 1582
59. Farmer R. D., Lawrenson R. A., Thompson C. R., Kennedy J. G., Hambleton I. R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet: 1997; 349 9045 83 88 (Pubitemid 27023424)
60. Lidegaard O, Lokkegaard E., Svendsen A. L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ: 2009; 339 2890
61. Vessey M., Mant D., Smith A., Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed): 1986; 292 6519 526 (Pubitemid 16126103)
62. Gerstman B. B., Piper J. M., Tomita D. K., Ferguson W. J., Stadel B. V., Lundin F. E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol: 1991; 133 1 32 37
63. Bloemenkamp K. W., Rosendaal F. R., Helmerhorst F. M., Büller H. R., Vandenbroucke J. P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet: 1995; 346 8990 1593 1596 (Pubitemid 26001841)
64. Lidegaard O, Nielsen L. H., Skovlund C. W., Skjeldestad F. E., Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ: 2011; 343 d6423
65. van den Heuvel M. W., van Bragt A. J., Alnabawy A. K., Kaptein M. C. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception: 2005; 72 3 168 174 (Pubitemid 41133355)
66. Cole J. A., Norman H., Doherty M., Walker A. M. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol: 2007; 109 2 pt 1 339 346 (Pubitemid 46197426)
67. Dore D. D., Norman H., Loughlin J., Seeger J. D. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception: 2010; 81 5 408 413
68. Jick S. S., Kaye J. A., Russmann S., Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception: 2006; 73 3 223 228 (Pubitemid 43202170)
69. Jick S. S., Hagberg K. W., Hernandez R. K., Kaye J. A. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception: 2010; 81 1 16 21
70. Bjarnadóttir R. I., Tuppurainen M., Killick S. R. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol: 2002; 186 3 389 395 (Pubitemid 34234146)
71. Oddsson K., Leifels-Fischer B., de Melo N. R., et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception: 2005; 71 3 176 182 (Pubitemid 40250198)
72. Ahrendt H. J., Nisand I., Bastianelli C., et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3. mg of drospirenone. Contraception: 2006; 74 6 451 457 (Pubitemid 46043314)
73. Kolacki C., Rocco V. The combined vaginal contraceptive ring, Nuvaring, and cerebral venous sinus thrombosis: a case report and review of the literature. J Emerg Med: 2012; 42 4 413 416
74. Daly E., Vessey M. P., Hawkins M. M., Carson J. L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet: 1996; 348 9033 977 980 (Pubitemid 26340751)
75. Jick H., Derby L. E., Myers M. W., Vasilakis C., Newton K. M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet: 1996; 348 9033 981 983 (Pubitemid 26340752)
76. Grodstein F., Stampfer M. J., Goldhaber S. Z., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet: 1996; 348 9033 983 987 (Pubitemid 26340753)
77. Pérez Gutthann S., García Rodríguez L. A., Castellsague J., Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ: 1997; 314 7083 796 800
78. Varas-Lorenzo C., García-Rodríguez L. A., Cattaruzzi C., Troncon M. G., Agostinis L., Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol: 1998; 147 4 387 390
79. Hoibraaten E., Abdelnoor M., Sandset P. M. Hormone replacement therapy with estradiol and risk of venous thromboembolisma population-based case-control study. Thromb Haemost: 1999; 82 4 1218 1221 (Pubitemid 29473780)
80. Smith N. L., Heckbert S. R., Lemaitre R. N., et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA: 2004; 292 13 1581 1587 (Pubitemid 39314964)
81. Cushman M., Kuller L. H., Prentice R., et al. Estrogen plus progestin and risk of venous thrombosis. JAMA: 2004; 292 13 1573 1580 (Pubitemid 39314963)
82. Grady D., Wenger N. K., Herrington D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med: 2000; 132 9 689 696 (Pubitemid 30244167)
83. Scarabin P. Y., Oger E., Plu-Bureau G. Estrogen and Thromboembolism Risk Study Group Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet: 2003; 362 9382 428 432 (Pubitemid 36999704)
84. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation: 2007; 115 7 840 845 (Pubitemid 46294724)
85. Straczek C., Oger E., Yon de Jonage-Canonico M. B., et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation: 2005; 112 22 3495 3500 (Pubitemid 43739566)
86. Canonico M., Oger E., Conard J., et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost: 2006; 4 6 1259 1265
87. Canonico M., Plu-Bureau G., Lowe G. D., Scarabin P. Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ: 2008; 336 7655 1227 1231 (Pubitemid 351809317)
88. Renoux C., Dell'Aniello S., Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost: 2010; 8 5 979 986
89. Canonico M., Fournier A., Carcaillon L., et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol: 2010; 30 2 340 345
90. Canonico M., Plu-Bureau G., Scarabin P. Y. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas: 2011; 70 4 354 360
91. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet: 2003; 361 9354 296 300 (Pubitemid 36126189)
92. Delmas P. D., Ensrud K. E., Adachi J. D., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab: 2002; 87 8 3609 3617 (Pubitemid 34879503)
93. Martino S., Cauley J. A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst: 2004; 96 23 1751 1761 (Pubitemid 39654569)
94. Adomaityte J., Farooq M., Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost: 2008; 99 2 338 342 (Pubitemid 351230964)
95. Taylor H. S., Ohleth K. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review. Menopause: 2012; 19 4 479 485
96. Ensrud K., LaCroix A., Thompson J. R., et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation: 2010; 122 17 1716 1724
97. Lee V. Y., Liu D. T., Li C. L., Hoi-Fan, Lam D. S. Central retinal vein occlusion associated with clomiphene-induced ovulation. Fertil Steril: 2008; 90 5 2011.e11 2011.e12
98. Viola M. I., Meyer D., Kruger T. Association between clomiphene citrate and visual disturbances with special emphasis on central retinal vein occlusion: a review. Gynecol Obstet Invest: 2011; 71 2 73 76